For instance, CD68+ TAMs were identified as predictors of favourable prognosis in gastric, colon and prostate adenocarcinomas, but as a predictor of poor prognosis in neuroblastoma, thyroid cancer and non-functioning pancreatic neuroendocrine tumours [38–44]. The gene discussed is CD68; the disease is prostate adenocarcinoma.